Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00154089 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia
A Phase 1 study, sponsored by Erimos Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00154089: Completed Phase 1 study, sponsored by Erimos Pharmaceuticals.
NCT00154089 is a Phase 1 study that has completed, run by Erimos Pharmaceuticals. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00154089, a Phase 1 study, has completed, sponsored by Erimos Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine pilot safety and efficacy data for a topical formulation of EM-1421 applied to the cervix of patients with CIN 1, 2, or 3.
Interventions
- DRUG EM-1421
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
What the finished NCT00154089 record still lists
NCT00154089 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which EM-1421 is the first listed.
NCT00154089 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00154089 about?
NCT00154089 is a clinical study titled "A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia". The primary objective of this study is to determine pilot safety and efficacy data for a topical formulation of EM-1421 applied to the cervix of patients with CIN 1, 2, or 3.
What is the current status of trial NCT00154089?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2004-11. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00154089?
The interventions under investigation include: EM-1421 (DRUG).
Who is sponsoring clinical trial NCT00154089?
This trial is sponsored by Erimos Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00154089's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-07-11
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT00177268 · started 2004-10
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT02280733 · started 2005-01-01
A Real-World Registry of Chronic Wounds and Ulcers
- NCT05899439 · started 2005-01-01
Immune Function and the Progression to T1D
- NCT00160771 · started 2005-01
Biomechanics/Motion Analysis Laboratory Data Bank